Rigel EVP uses 3,546 shares for tax withholding

Q: What insider transaction did RIGL executive Raymond J. Furey report?

Raymond J. Furey reported a tax-withholding disposition of 3,546 Rigel common shares on February 10, 2026. The Form 4 shows this was to cover obligations rather than an open-market buy or sell transaction.

Q: How many RIGL shares did Raymond J. Furey dispose of and at what price?

He disposed of 3,546 shares of Rigel common stock at $34.62 per share. The filing characterizes this as a tax-related transaction under code F, which is used for covering exercise price or tax liabilities with shares.

Q: How many Rigel (RIGL) shares does Raymond J. Furey own after this transaction?

After the reported transaction, Raymond J. Furey directly owns 32,316 shares of Rigel common stock. This figure comes from the post-transaction ownership column in the Form 4, reflecting his remaining direct holdings.

Q: What does transaction code F mean in the RIGL Form 4 filing?

Transaction code F indicates payment of exercise price or tax liability by delivering securities. In this case, 3,546 Rigel shares were used to satisfy tax obligations, rather than being sold in a traditional open-market trade.

Q: What is Raymond J. Furey’s role at Rigel Pharmaceuticals (RIGL)?

Raymond J. Furey is listed as an officer of Rigel Pharmaceuticals with the title “EVP, GC, CCO & Corp Sec.” This means he serves as Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary.

Q: Was the RIGL insider transaction a direct or indirect ownership change?

The filing shows the transaction as direct ownership (code D). This indicates the 3,546 shares used for tax withholding, and the remaining 32,316 shares, are held directly by Raymond J. Furey rather than through an intermediary entity.

Rigel Pharmaceuticals executive Raymond J. Furey disposed of 3,546 shares of common stock on February 10, 2026 to satisfy tax obligations.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Rigel Pharmaceuticals executive Raymond J. Furey disposed of 3,546 shares of common stock on February 10, 2026 to satisfy tax obligations. The tax-withholding disposition, reported under transaction code F at a share price of $34.62, left him holding 32,316 shares of Rigel common stock directly.

Insider Trade Summary

Exercise Price or Tax Liability: 3,546 shares

Exercise Price or Tax Liability 1 txn

Insider Furey Raymond J.

Role EVP, GC, CCO & Corp Sec

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	3,546	$34.62	$123K

Holdings After Transaction: Common Stock — 32,316 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RIGL executive Raymond J. Furey report?

Raymond J. Furey reported a tax-withholding disposition of 3,546 Rigel common shares on February 10, 2026. The Form 4 shows this was to cover obligations rather than an open-market buy or sell transaction.

How many RIGL shares did Raymond J. Furey dispose of and at what price?

He disposed of 3,546 shares of Rigel common stock at $34.62 per share. The filing characterizes this as a tax-related transaction under code F, which is used for covering exercise price or tax liabilities with shares.

How many Rigel (RIGL) shares does Raymond J. Furey own after this transaction?

After the reported transaction, Raymond J. Furey directly owns 32,316 shares of Rigel common stock. This figure comes from the post-transaction ownership column in the Form 4, reflecting his remaining direct holdings.

What does transaction code F mean in the RIGL Form 4 filing?

Transaction code F indicates payment of exercise price or tax liability by delivering securities. In this case, 3,546 Rigel shares were used to satisfy tax obligations, rather than being sold in a traditional open-market trade.

What is Raymond J. Furey’s role at Rigel Pharmaceuticals (RIGL)?

Raymond J. Furey is listed as an officer of Rigel Pharmaceuticals with the title “EVP, GC, CCO & Corp Sec.” This means he serves as Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary.

Was the RIGL insider transaction a direct or indirect ownership change?

The filing shows the transaction as direct ownership (code D). This indicates the 3,546 shares used for tax withholding, and the remaining 32,316 shares, are held directly by Raymond J. Furey rather than through an intermediary entity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/12/2026 - 04:50 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Furey Raymond J.

(Last)

(First)

(Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, GC, CCO & Corp Sec

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/10/2026		F		3,546	D	$34.62	32,316	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

	/s/ Raymond Furey	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR